For the annual congress of the Portuguese Inflammatory Bowel Disease Study Group (GEDII 2021), Adacyte Therapeutics went to Porto to share its experiences in ulcerative colitis and Crohn’s disease.
October 19, 2021
From 22nd to 24th September Adacyte was able, in contact with doctors from different countries, to exchange and share their experience and knowledge about new treatments for Crohn’s disease and ulcerative colitis. Adacyte, loyal to its commitment to patient’s health, has continued to work hard during this congress to promote Adacolumn®. We tried our best to show Portuguese experts in IBD the existing real-world evidence of the Adacolumn® beneficial effects in reduction of inflammation and remission of the disease. Adacolumn® is a unique non-pharmaceutical treatment using therapeutic granulocyte and monocyte apheresis, whether in terms of efficacy or safety.
Highlights of the GEDII Congress
On the morning of the first day of the congress, a training session was held on the procedure for publication in scientific journals in which many young doctors participated. It was then followed by an advanced course in IBD monitoring with biomarkers.
In general, during the second day the scientific program was very complete with a review of interesting topics such as imaging techniques, the establishment of quality standards, IBD complications and new treatments.
Contact UsFor more informationContact Us